BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Cut to $81.00 by Analysts at Citigroup

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) had its target price cut by equities research analysts at Citigroup from $93.00 to $81.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a "neutral" rating on the biotechnology company's stock. Citigroup's price target would indicate a potential upside of 20.12% from the stock's current price.

A number of other brokerages also recently issued reports on BMRN. Piper Sandler upped their price objective on shares of BioMarin Pharmaceutical from $107.00 to $122.00 and gave the stock an "overweight" rating in a research report on Thursday, September 5th. UBS Group boosted their price objective on BioMarin Pharmaceutical from $104.00 to $106.00 and gave the company a "buy" rating in a research report on Wednesday. Evercore ISI dropped their price target on shares of BioMarin Pharmaceutical from $115.00 to $105.00 and set an "outperform" rating for the company in a research report on Wednesday. Canaccord Genuity Group lowered their target price on BioMarin Pharmaceutical from $93.00 to $84.00 and set a "hold" rating for the company in a research note on Wednesday. Finally, Cantor Fitzgerald decreased their price objective on BioMarin Pharmaceutical from $110.00 to $90.00 and set an "overweight" rating for the company in a report on Wednesday. Eight research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $93.67.

BioMarin Pharmaceutical Trading Down 3.5 %

BioMarin Pharmaceutical stock traded down $2.48 during mid-day trading on Wednesday, hitting $67.43. 1,806,693 shares of the stock were exchanged, compared to its average volume of 1,844,235. The firm's fifty day simple moving average is $76.60 and its two-hundred day simple moving average is $81.04. The company has a quick ratio of 1.95, a current ratio of 3.05 and a debt-to-equity ratio of 0.11. BioMarin Pharmaceutical has a 12 month low of $65.78 and a 12 month high of $99.56. The stock has a market capitalization of $12.80 billion, a price-to-earnings ratio of 62.91, a PEG ratio of 0.81 and a beta of 0.31.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.55 EPS for the quarter, missing the consensus estimate of $0.78 by ($0.23). The firm had revenue of $746.00 million for the quarter, compared to the consensus estimate of $703.37 million. BioMarin Pharmaceutical had a net margin of 9.91% and a return on equity of 6.91%. The company's revenue was up 28.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.26 EPS. Analysts forecast that BioMarin Pharmaceutical will post 2.39 EPS for the current year.

Hedge Funds Weigh In On BioMarin Pharmaceutical

A number of hedge funds and other institutional investors have recently modified their holdings of BMRN. Envestnet Portfolio Solutions Inc. lifted its holdings in BioMarin Pharmaceutical by 1.2% during the first quarter. Envestnet Portfolio Solutions Inc. now owns 10,668 shares of the biotechnology company's stock worth $932,000 after buying an additional 130 shares during the period. Quent Capital LLC boosted its stake in shares of BioMarin Pharmaceutical by 58.9% in the second quarter. Quent Capital LLC now owns 391 shares of the biotechnology company's stock worth $32,000 after buying an additional 145 shares during the last quarter. Voisard Asset Management Group Inc. grew its position in BioMarin Pharmaceutical by 17.8% during the third quarter. Voisard Asset Management Group Inc. now owns 1,355 shares of the biotechnology company's stock valued at $95,000 after buying an additional 205 shares during the period. Grandfield & Dodd LLC raised its holdings in BioMarin Pharmaceutical by 1.6% in the 1st quarter. Grandfield & Dodd LLC now owns 16,127 shares of the biotechnology company's stock worth $1,409,000 after purchasing an additional 255 shares during the period. Finally, AIA Group Ltd grew its position in shares of BioMarin Pharmaceutical by 7.0% in the first quarter. AIA Group Ltd now owns 4,076 shares of the biotechnology company's stock valued at $356,000 after purchasing an additional 266 shares during the period. 98.71% of the stock is currently owned by institutional investors.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.